- Home
- RFAM vs ANTX Comparison
RFAM vs ANTX Comparison
Compare RFAM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFAM | ANTX |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.4M | 158.8M |
| IPO Year | 2026 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RFAM | ANTX |
|---|---|---|
| Price | $9.93 | $4.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 6.4K | ★ 442.7K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $1.00 |
| 52 Week High | $9.94 | $6.91 |
Technical Indicators
Market Signals| Indicator | RFAM | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 56.04 |
| Support Level | $9.77 | $3.91 |
| Resistance Level | $9.92 | $5.13 |
| Average True Range (ATR) | 0.00 | 0.35 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.50 | 67.83 |
Price Performance
Historical ComparisonAbout RFAM RF Acquisition Corp III Ordinary Shares
RF Acquisition Corp III is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.